Program
duvelisib
Also written as “Duvelisib”, “IPI-145” and “IPI-145 (duvelisib)”.
Its studies are mostly in Leukemia, Lymphocytic, Chronic, B-Cell · Lymphoma · Lymphoma, Follicular · Hematologic Neoplasms · Mycosis Fungoides, led by 3 companies.
Drug pageDuvelisib: every studyAll 50 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| SecuraBioits history only | 232 open or running | phase 3since Nov 13, 2013 | Nov 17, 2011 | Feb 2028phase 3 · NCT06522737 |
| AbbVieits history only | 20 open or running | phase 1since Oct 21, 2015 | Oct 21, 2015 | none ahead |
| CSPC Pharmaceutical Group | 10 open or running | phase 2since Apr 24, 2020 | Apr 24, 2020 | none ahead |
Also a collaborator on its studies: Infinity Pharmaceuticals.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of CSPC Pharmaceutical Group only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 24, 2020First study: phase 2 study in Lymphoma, FollicularFirst studyNCT04707079 · 24 enrolled · China
TargetBeta
“PI3-kinase p110-delta subunit inhibitor; PI3-kinase p110-gamma subunit inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| gedatolisibrule | Pfizer | phase 3 | 9 |
| paxalisibrule | kazia-therapeutics-limited | phase 2 | 4 |
Studies
The one study CSPC Pharmaceutical Group leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT04707079Lymphoma, Follicular · China | 2 | UNKNOWN | Oct 31, 2021 | 24 |
How it is read
Names in the registry
- “Duvelisib”, 16 entries
- “IPI-145”, 9 entries
- “IPI-145 (duvelisib)”, 3 entries
- “IPI-145, a PI3K Inhibitor”, 1 entry
- “duvelisib”, 1 entry
Conditions, from the studies’ own filings
- Leukemia, Lymphocytic, Chronic, B-Cell, 5 studies
- Lymphoma, 3 studies
- Lymphoma, Follicular, 3 studies
- Hematologic Neoplasms, 2 studies
- Mycosis Fungoides, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.